Sudeep Pharma IPO opens tomorrow; grey market premium jumps 22%
What's the story
Sudeep Pharma, a technology-driven manufacturer of excipients and specialty ingredients, will launch its initial public offering (IPO) on November 21. The company has fixed the price band for its maiden issue at ₹563-₹593 per share. The IPO consists of a fresh issue worth ₹95 crore and an offer for sale (OFS) of up to 1.35 crore equity shares worth ₹800 crore by promoter and promoter group shareholders.
Subscription specifics
Sudeep Pharma's IPO details and subscription process
The Sudeep Pharma IPO will be open for subscription until November 25, 2025. Investors can bid for a minimum of 25 equity shares and in multiples of 25 thereafter. The company plans to use ₹75.81 crore from the fresh issue toward capital expenditure for procuring machinery at its Nandesari Facility in Gujarat, with the remaining funds going toward general corporate purposes.
Market reach
Sudeep Pharma's global presence and client base
Sudeep Pharma has a strong global presence across over 100 countries, including the US, South America, Europe, the Middle East, Africa, and Asia-Pacific. The company is one of the largest manufacturers of food-grade iron phosphate for infant nutrition and food & beverage applications. It has an annual manufacturing capacity of 72,246 metric tons as of June 30. Sudeep Pharma's client list includes Pfizer, Mankind Pharma, Intas Pharmaceuticals, Merck Group, Alembic, Aurobindo Pharma, Cadila Pharmaceuticals, Micro Labs, Danone, and more.
Financials
Sudeep Pharma's financial performance and IPO lead managers
In FY25, Sudeep Pharma reported a revenue of ₹511.33 crore, up from ₹465.38 crore in FY24. Its net profit also increased marginally to ₹138.69 crore in FY25 from ₹133.15 crore in the previous fiscal year. ICICI Securities and IIFL Capital Services are the book-running lead managers to the issue while MUFG Intime India is the registrar for this IPO. Listing on BSE and NSE is planned for November 28 after share allotment on November 26.